Quoin Prices $50M Private Placement at $4.88/ADS with Insider Participation
QNRX has more than doubled off its 52-week low of $3.25 on elevated volume (39× avg).
Summary
Quoin Pharmaceuticals priced a $50M private placement at $4.88/ADS with insider participation, extending its cash runway into 2029 while diluting existing shareholders.
Key Events · Financing and Capital Events · QNRX
-
$50M Private Placement Priced
Quoin entered a Securities Purchase Agreement for up to $50M in gross proceeds: $30.8M upfront at closing (expected August 31, 2026) plus up to $19.2M from potential cash exercise of ordinary warrants.
-
Pricing and Warrant Terms
6,305,300 ADSs (or pre-funded warrants) issued at $4.88 per ADS with accompanying ordinary warrants exercisable at $6.10 per ADS. Ordinary warrants expire in 5 years or 30 days after the primary endpoint is met in CL-QRX003-004.
-
Insider Participation
Directors and officers purchased 57,370 ADSs and accompanying warrants for approximately $280,000 at the same $4.88 price, approved by the Audit Committee and Board.
-
Legacy Debt Settled with Equity
Quoin issued 222,574 ADSs to three 2020 Noteholders (including two directors) to satisfy $1,146,000 of accrued and unpaid interest from the 2020 merger.
Analysis · QNRX · Life Sciences
Quoin Pharmaceuticals priced a private placement of up to $50 million at $4.88 per ADS, with $30.8 million expected upfront at closing on August 31, 2026. The deal includes ordinary warrants exercisable at $6.10 per ADS that could add another $19.2 million if exercised. Directors and officers are participating with a $280,000 purchase, and the company is also issuing 222,574 ADSs to settle $1.15 million of legacy debt. The financing extends Quoin's cash runway into the second half of 2029, addressing the going-concern risk flagged in its August 14 10-Q. The pricing is at the Nasdaq minimum price plus $0.0625, reflecting the company's constrained negotiating position, but the participation of healthcare-focused institutional investors and insiders provides some validation. The deal is dilutive to existing holders, but the capital is critical for completing the Phase 2/3 trial of QRX003 in Netherton Syndrome, which reported positive interim data the same day.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.8% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.82%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNRX was trading at $6.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $3.25 to $41.80. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.